antifungal agent

(redirected from itraconazole)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.

antifungal agent

[‚an·tē′fəŋ·gəl ‚ā·jənt]
(materials)
A chemical compound that either destroys or inhibits the growth of fungi.
References in periodicals archive ?
Fluconazole is generally considered to be superior to itraconazole for the management of fungal CNS infections, particularly meningitis caused by Coccidioides immitis and cryptococcal meningitis.
He was found to have isolated colonic histoplasmosis infection, which was treated with itraconazole.
Previous treatment included systemic itraconazole alone in 5 patients and systemic itraconazole and oral prednisone in 8 patients.
Maintenance regimens that have demonstrated effectiveness in published studies include 150 mg of oral fluconazole once per week, oral ketoconazole at 100 mg once daily, oral itraconazole at 100 mg once daily, a single 500-mg tablet of clotrimazole administered intravaginally once weekly, or a daily azole cream.
In rat pharmacokinetic studies, itraconazole showed a long duration of lung retention, with some clearance over a one week period.
If you search in the US government's PubMed index of medical literature, you come across about 750 articles that reference itraconazole and cancer.
The infection was successfully treated with surgery and itraconazole therapy for 12 months.
Postoperative treatment consisted of meloxicam, trimethoprim sulfa, amphotericin B by nebulization, and systemic itraconazole and fluconazole.
More than 1,000 clinical isolates from 22 states were screened by using an itraconazole antifungal plate assay and the Etest to measure itraconazole MICs.
Acetaminophen Nifedipine Everolimus Nabilone Diethylpropion Emend Vildagliptin/Metformin Clozapine Fenofibrate Griseofulvin Ibuprofen Etonogestrel Etravirine Verapamil Liponavir+Ritonavir Lacrisert Tacrolimus Rizatriptan Naproxen Norvir Tapentadol Etonogestrel, Ethinyl Estradiol Itraconazole Dexamethasone Hydromorphone Rapamune Tricor, Triglide Zoladex
ABSTRACT Currently approved options for the treatment of onychomycosis include systemic therapy (the antifungal agents fluconazole, itraconazole, and terbinafine), topical agents (ciclopirox, which has been available since 1996, efinaconazole, currently pending approval), and laser systems.